Wawira Njiru’s TED Talk Unveils Africa’s Blueprint to End Classroom Hunger
30.7.2025 10:00:00 CEST | Business Wire | Press Release
As the UN Food Systems Summit +4 wraps up in Addis Ababa, Wawira Njiru, Founder and CEO of Food4Education, takes the TED stage with a powerful message: Africa is not waiting for answers, it’s creating them.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250730384724/en/
Wawira Njiru, Founder and CEO of Food4Education, spotlights Tap2Eat — the NFC wristband powering Kenya’s school feeding infrastructure for over 500,000 children — giving them dignified, cashless access to school meals while using real‑time data to connect education, nutrition, and local economies.
In her TED Talk released today [go.ted.com/wawiranjiru], food systems trailblazer Njiru tells the story of how a simple act of care — feeding 25 children in a makeshift kitchen — sparked a bold, locally-led solution now delivering over 500,000 meals every day. Today, Food4Education is the backbone of Kenya’s school feeding infrastructure and a blueprint for countries across Africa investing in nutrition, education, and opportunity all at once.
“School feeding isn’t charity, it’s strategy, it’s infrastructure,” said Njiru. “It’s how we nourish children, support farmers, strengthen education, and build systems that last. We’ve created a sustainable solution that shows Africa isn’t just solving its own challenges — we’re setting precedents the world can learn from.”
Built on public–private partnership, Food4Education combines government co-investment, parent contributions, and philanthropic force to power its industry-redefining solution. Its green kitchens run on clean energy. Its meals are sourced from local smallholder farmers. Its systems are digital, dignified, and built for scale, with every plate powering learning, livelihoods, and long-term opportunity.
Taking the stage as part of The Audacious Project 2024’s cohort, Njiru’s TED Talk comes at a time of renewed global attention on school feeding as a proven lever for inclusive, sustainable development. With Africa home to the youngest population on Earth, and 1 in 4 people projected to be African by 2050, how the continent feeds its children today will shape the future we all share.
“There’s no debate: school meals are among the most effective, scalable tools to strengthen food systems, linking education, nutrition, agriculture, and local economies,” said Shalom Ndiku, Director of Public Affairs at Food4Education. “At UNFSS+4, it was a proud moment for our whole team to see our work recognized as a flagship intervention in Kenya’s national report. It’s a testament to the collective effort driving sustainable, African-led school feeding systems.”
This is not just a Kenyan story. It’s a global opportunity. This TED milestone reflects a growing movement and global recognition that African solutions, grown and led locally, can transform systems at scale.
TED2025’s theme, Humanity Reimagined, celebrates bold ideas redefining the future. Njiru’s TED Talk, From Origin to Opportunity, reframes hunger through three bold provocations:
- School meals are infrastructure. Hunger, education, and opportunity are interconnected. Feeding children well powers learning, health, and livelihoods all at once.
- Locally-led solutions work. Food4Education grew from 25 meals to 500,000 a day by investing in African ingenuity, community ownership, and public partnership.
- Africa can lead the way. With 1 in 4 people projected to be African by 2050, the systems we build on the continent today will shape the world tomorrow.
Watch the TED Talk: Understand the depth and impact of Food4Education’s work and engage with the vision go.ted.com/wawiranjiru
Support the movement: Contribute to the ongoing efforts to make classroom hunger history and to empower the next generation of African leaders www.food4education.org/donate
Hungry kids can’t learn or grow.
Food4Education is an award-winning, locally rooted, and African-led solution to end classroom hunger. Building on more than a decade of learning by doing, we’re powering a new school feeding industry and sharing our blueprint to scale sustainable, nutritious, and affordable school feeding programs across Africa.
Today, we serve half a million kids DAILY in Kenya. But every day, we deliver more than a meal — improving nutrition and education outcomes for children while also creating jobs and opportunities for whole communities.
We are an experienced and trusted non-profit partner that operates with the excellence of a global business, reinvesting the value we create into local economies.
To learn more, please visit www.food4education.org.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250730384724/en/
Contacts
Press contact:
Nelly Gitau | Communications Manager | communications@food4education.org
f4e@allisonworldwide.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom